Cagrilintide vs Tirzepatide: Weight Loss Peptides Compared
Written by NorthPeptide Research Team | Reviewed February 2, 2026
By the NorthPeptide Research Team — Updated February 2026
Mechanism: Two Different Pathways to Weight Reduction
Cagrilintide: Amylin Analogue
Cagrilintide mimics amylin, a peptide hormone co-secreted with insulin from pancreatic beta cells. Amylin regulates gastric emptying, suppresses glucagon, and acts centrally in the hypothalamus to reduce food intake. Cagrilintide’s key characteristics:
- Binds amylin receptors (AMY1, AMY2, AMY3) and calcitonin receptors
- Slows gastric emptying, reducing post-meal glucose spikes
- Reduces appetite via central hypothalamic pathways
- Once-weekly dosing achieved through fatty acid acylation (similar engineering to semaglutide)
Tirzepatide: Dual GIP/GLP-1 Agonist
Tirzepatide is a twincretin — it activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This dual activation distinguishes it from pure GLP-1 agonists like semaglutide:
- GLP-1 receptor activation reduces appetite and slows gastric emptying
- GIP receptor activation may enhance insulin sensitivity in adipose tissue and work synergistically with GLP-1
- Once-weekly subcutaneous injection
- FDA-approved for type 2 diabetes (Mounjaro) and obesity (Zepbound)
Clinical Trial Data Comparison
Tirzepatide (SURMOUNT Trials)
The SURMOUNT-1 trial enrolled adults with obesity but without diabetes. Key results at 72 weeks:
- 5 mg dose: average 15% body weight reduction
- 10 mg dose: average 19.5% body weight reduction
- 15 mg dose: average 20.9% body weight reduction
- Placebo: average 3.1% body weight reduction
These results established tirzepatide as one of the most effective pharmaceutical weight loss interventions in history at the time of publication.
Cagrilintide (Phase II Data)
Cagrilintide monotherapy Phase II data showed approximately 10–12% body weight reduction at the highest dose (4.5 mg weekly) vs. placebo over 26 weeks. While meaningful, this is lower than tirzepatide’s monotherapy figures.
CagriSema: The Combination Approach
The most significant development in cagrilintide research has been its combination with semaglutide as “CagriSema.” Phase II data from the REDEFINE trials showed:
- Average body weight reduction of ~22–24% at the highest dose over 68 weeks
- Numerically superior to semaglutide 2.4 mg monotherapy (which averages ~15%)
- Combination appears synergistic, suggesting amylin and GLP-1 pathways complement each other
This positions CagriSema as a potential competitor to tirzepatide in the obesity treatment landscape, with Phase III trials ongoing.
Side Effect Profiles
Both compounds share the class-typical gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) associated with incretins and satiety hormones. Cagrilintide appears to have a somewhat lower nausea burden than GLP-1 monotherapy at equivalent weight-loss efficacy, though direct head-to-head safety comparisons are limited.
Research Products
Browse All Research Peptides
High-purity compounds. Third-party tested. For laboratory research use only.
Related Research Articles
PubMed Citations
| Study | Finding |
|---|---|
| Jastreboff et al. (2022) — NEJM (SURMOUNT-1) | Tirzepatide 15mg achieved 20.9% mean weight reduction vs 3.1% placebo at 72 weeks |
| Enebo et al. (2021) — Lancet Diabetes Endocrinol | Cagrilintide 4.5mg monotherapy: ~12% weight reduction over 26 weeks, dose-dependent |
| Lau et al. (2021) — Cell Metab | Amylin-GLP-1 combination showed additive appetite suppression in rodent and non-human primate models |